De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

MedinCell Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Christophe Douat

Algemeen directeur

€781.5k

Totale compensatie

Percentage CEO-salaris	38.0%
Dienstverband CEO	10.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	4.1yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be

Jul 05

Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%

Apr 26

Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher

Jan 09

The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On

Mar 02

Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?

Jan 08

Analyse CEO-vergoeding

Hoe is Christophe Douat's beloning veranderd ten opzichte van MedinCell's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	€782k	€297k	-€25m
Dec 31 2023	n/a	n/a	-€26m
Sep 30 2023	n/a	n/a	-€26m
Jun 30 2023	n/a	n/a	-€29m
Mar 31 2023	€522k	€267k	-€32m
Dec 31 2022	n/a	n/a	-€29m
Sep 30 2022	n/a	n/a	-€27m
Jun 30 2022	n/a	n/a	-€26m
Mar 31 2022	€329k	€258k	-€25m
Dec 31 2021	n/a	n/a	-€22m
Sep 30 2021	n/a	n/a	-€20m
Jun 30 2021	n/a	n/a	-€19m
Mar 31 2021	€336k	€235k	-€19m
Dec 31 2020	n/a	n/a	-€22m
Sep 30 2020	n/a	n/a	-€26m
Jun 30 2020	n/a	n/a	-€25m
Mar 31 2020	€301k	€232k	-€24m
Dec 31 2019	n/a	n/a	-€21m
Sep 30 2019	n/a	n/a	-€19m
Jun 30 2019	n/a	n/a	-€19m
Mar 31 2019	€244k	€192k	-€20m
Dec 31 2018	n/a	n/a	-€17m
Sep 30 2018	n/a	n/a	-€15m
Jun 30 2018	n/a	n/a	-€12m
Mar 31 2018	€175k	€149k	-€10m

Compensatie versus markt: De totale vergoeding ($USD 865.10K ) Christophe } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de French markt ($USD 557.83K ).

Compensatie versus inkomsten: De vergoeding van Christophe is gestegen terwijl het bedrijf verliesgevend is.

CEO

Christophe Douat (58 yo)

10.3yrs

Tenure

€781,528

Compensatie

Mr. Christophe Douat has been the Chief Executive Officer of MedinCell S.A and serves as its Director since September 12, 2024. He served as Chairman of the Management Board at MedinCell S.A until Septembe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Christophe Douat	Chief Executive Officer & Director	10.3yrs	€781.53k	geen gegevens
Franck Pouzache	Chief People Officer & Member of the Management Board	4.5yrs	€383.09k	geen gegevens
Stephane Postic	Chief Financial Officer	1.1yrs	geen gegevens	geen gegevens
Julie Alimi	Head of Legal	3.8yrs	geen gegevens	geen gegevens
David Heuze	Head of Communications	no data	geen gegevens	geen gegevens
Adolfo Lopez-Noriega	Head of Research & Development	no data	geen gegevens	geen gegevens
Sebastien Enault	Chief Business Officer	2.8yrs	geen gegevens	geen gegevens
Helen Martin	Head of Alliance & Project Management	5.3yrs	geen gegevens	geen gegevens
Quiterie Beauregard	Head of Global Health Development	7.9yrs	geen gegevens	geen gegevens
Richard Malamut	Chief Medical Officer	2.5yrs	geen gegevens	geen gegevens
Stephane Chambaud	Head of Pharmaceutical Operations	no data	geen gegevens	geen gegevens
Nicolas Gourgues	Senior Communications Officer	no data	geen gegevens	geen gegevens

4.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van MEDCL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Christophe Douat	Chief Executive Officer & Director	less than a year	€781.53k	geen gegevens
Tone Kvale	Director	less than a year	€25.00k	geen gegevens
Olivier-Sabri Markabi	Director	less than a year	€26.50k	geen gegevens
Philippe Guy	Chairman of the Board	less than a year	€28.00k	geen gegevens
Virginie Lleu	Director	less than a year	€25.00k	geen gegevens
Rachel Almeras	Censor	no data	geen gegevens	geen gegevens
Elizabeth Kogan	Director	less than a year	€21.00k	geen gegevens

0.08yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MEDCL wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.1 jaar), wat duidt op een nieuw bestuur.

MedinCell Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

MedinCell S.A. Confirms Stéphane Postic as CFO

Medincell S.A. Appoints Philippe Guy as Chairman of Supervisory Board

MedinCell Announces Chairman Changes

MedinCell S.A., Annual General Meeting, Sep 12, 2024

MedinCell S.A., Annual General Meeting, Sep 12, 2023

MedinCell Appoints Richard Malamut, MD as Chief Medical Officer

Recent updates

MedinCell S.A. Confirms Stéphane Postic as CFO

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be

Consensus revenue estimates fall by 22%

Price target increased by 8.6% to €20.03

New major risk - Financial position

Full year 2024 earnings released

Consensus revenue estimates fall by 14%

Medincell Provides Update on Phase 3 mdc-CWM Clinical Trial

Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%

New minor risk - Share price stability

Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy™ for the Treatment of Schizophrenia

Medincell S.A. Appoints Philippe Guy as Chairman of Supervisory Board

MedinCell Announces Chairman Changes

MedinCell S.A., Annual General Meeting, Sep 12, 2024

Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable

Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher

Consensus revenue estimates increase by 13%

First half 2024 earnings released

Medincell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (Mdc-Cwm), A First-In-Class Therapy for Localized Pain Relief After Total Knee Replacement

New minor risk - Shareholder dilution

Consensus revenue estimates fall by 42%

Full year 2023 earnings released

Price target increased by 9.8% to €16.10

Forecast breakeven date pushed back to 2025

Consensus revenue estimates fall by 42%

Medincell Announces Positive Results for the Saive Clinical Study in Prevention of Covid-19 Infection in A Contact-Based Population

MedinCell S.A., Annual General Meeting, Sep 12, 2023

MedinCell S.A. to Report First Half, 2024 Results on Dec 06, 2023

First half 2023 earnings released: €0.55 loss per share (vs €0.47 loss in 1H 2022)

Price target decreased to €14.50

MedinCell Announces the Initiation of Phase 3 Study of F14 (mdc-CWM), A Therapeutic First-In-Class That Aims to Provide Weeks of Localized Pain Relief After Total Knee Replacement

Price target decreased to €14.50

Full year 2022 earnings: Revenues miss analyst expectations

MedinCell Appoints Richard Malamut, MD as Chief Medical Officer

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

MedinCell S.A. Announces Inclusion of First Participants in New Covid-19 Prophylaxis Clinical Trial SAIVE

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MedinCell Provides an Update on Its Product Portfolio, Following the FDA Acceptance of New Drug Application for the Product mdc-IRM

Teva Pharmaceuticals and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as Treatment for Patients with Schizophrenia

Full year 2021 earnings released

Medincell Collaborates for More Than 10 Years with Ird, Irss and Cirdes to Conduct in Vivo Studies in Burkina Faso About Tackling Residual Transmission of Malaria

The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On

MedinCell Announces Three New Products Entering Regulatory Development

MedinCell S.A., Annual General Meeting, Sep 10, 2021

New 90-day high: €16.15

Analysts lower revenue estimates to €11.4m

Teva Pharmaceuticals Industries Ltd. and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia

Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?

New 90-day high: €15.00

First half 2021 earnings released: €0.51 loss per share

New 90-day high: €9.50

New 90-day high: €8.12

MedinCell Initiates the First Clinical Trial of its Covid-19 Prevention Program

New 90-day low - €7.04

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd